Chemours (NYSE:CC) Given New $21.00 Price Target at Mizuho

Chemours (NYSE:CC) had its target price decreased by Mizuho from $22.00 to $21.00 in a research note published on Tuesday morning,Benzinga reports. Mizuho currently has a neutral rating on the specialty chemicals company’s stock.

CC has been the topic of several other research reports. The Goldman Sachs Group decreased their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research note on Tuesday. BMO Capital Markets lifted their price objective on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, October 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $25.00 target price on shares of Chemours in a report on Thursday, December 12th. Morgan Stanley dropped their price target on shares of Chemours from $30.00 to $25.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 5th. Finally, Barclays increased their price objective on Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $24.13.

Chemours Trading Down 4.7 %

Shares of CC stock opened at $17.87 on Tuesday. Chemours has a 1-year low of $15.10 and a 1-year high of $32.48. The firm has a market cap of $2.67 billion, a PE ratio of 35.74 and a beta of 1.83. The company has a 50-day moving average of $19.28 and a two-hundred day moving average of $19.94. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92.

Chemours (NYSE:CC) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The firm had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.44 billion. During the same quarter last year, the firm earned $0.64 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts predict that Chemours will post 1.35 EPS for the current year.

Chemours Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 15th were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.60%. Chemours’s payout ratio is currently 200.00%.

Insider Activity at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now directly owns 16,645 shares of the company’s stock, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.47% of the stock is currently owned by corporate insiders.

Institutional Trading of Chemours

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its position in shares of Chemours by 3.5% in the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company’s stock valued at $368,650,000 after buying an additional 618,361 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Chemours by 23.8% during the second quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company’s stock worth $158,213,000 after purchasing an additional 1,347,710 shares during the last quarter. Khrom Capital Management LLC increased its position in shares of Chemours by 54.6% during the second quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock worth $78,016,000 after purchasing an additional 1,220,967 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Chemours by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company’s stock valued at $50,646,000 after purchasing an additional 28,803 shares during the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Chemours by 26.7% in the 2nd quarter. American Century Companies Inc. now owns 1,811,957 shares of the specialty chemicals company’s stock valued at $40,896,000 after purchasing an additional 382,100 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.